Market Research Blog

As the prevalence of lung cancer, melanoma, and renal cell carcinoma continues to soar worldwide, the adoption of PD-L1 biomarker testing is expected to grow at a healthy pace in the years to come, says Future Market Insights (FMI) in its new market study. Moreover, the report forecasts that the global PD-L1 biomarker testing market will grow in value at a stellar CAGR of 13.1% between 2020 and 2030.

The report opines that the outbreak of COVID-19 is likely to create short-term fluctuations on the supply side due to pandemic-related issues such as workforce shortages and disruptions of delivery networks. Similarly, a steep decline in the number of tests has been observed during the pandemic, and this is expected to further decelerate the demand for PD-L1 biomarker testing.

The report primarily attributes the growth of the market to the increasing incidence of cancers, especially lung and skin, coupled with the development of advanced diagnostic kits and assays.

Click the link to get a free Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5897

Likewise, rising awareness regarding the availability of testing methodology such as immunohistochemistry-based assays and Enzyme-linked Immunoassay (ELISA) based detection will continue to impel the adoption of PD-L1 biomarkers in the forthcoming years.

Key Takeaways

• The global PD-L1 biomarkers testing market is expected to surge past valuation of US$ 2.05 Bn by the end of the forecast period.
• PD-L1 SP142 assay kits will remain the most popular products among end-users, capturing nearly half of the market value, owing to high efficiency in detecting cancer tumors.
• Non-small cell lung cancer and melanoma are cumulatively expected to hold more than 50% of the total market value on the back of the soaring prevalence of these diseases.
• By end-use, PD-lL1 biomarker testing finds the majority of applications in hospitals, which is expected to account for over 60% of market value.
• North America will spearhead the regional landscape through the forecast period, accounting for more than 50% of the global market value.
• Europe is poised to remain the second most lucrative region, holding nearly 1/3rd of market value.

“Market players are directing their efforts towards improving the accessibility of these products and are marking them cost-effective to ensure wide-scale adoption,” remarks FMI analyst.

COVID-19 Impact on PD-L1 Biomarker Testing Market

The COVID-19 pandemic has created disruptions across the healthcare technology landscape and has resulted in a shifting preference among manufacturers towards essential technologies and treatments. Furthermore, although PD-L1 biomarker testing is used to test severe diseases such as cancer, a reduced number of screenings is adversely impacting the demand for testing.

For instance, according to trends observed by Cancer Research Network, screening rates of melanoma plummeted by approximately 50% in the UK in the past few months. Likewise, in the US, the number of tests conducted to detect non-small cell lung cancer fell by 30% in March as compared to February. As patients reschedule or skip regular screenings, this is creating a downtrend in demand for PL-D1 biomarker testing.

However, considering the severity of these diseases, the need for testing will swiftly arise in the future, ensuring that the market’s growth trajectory remains intact.

Who is Winning?

Key players operating in the market are focusing on enhancing existing product designs and developing novel products with increased accuracy. Moreover, traditional growth strategies such as acquisitions and mergers have been identified as strategies adopted by players to strengthen their foothold in the competitive landscape.

• In January 2019, Abcam Plc acquired Calico Biolabs with an objective to expand its custom monoclonal production service capabilities.
• In December 2018, NeoGenomics, Inc. acquired Genoptix, Inc. to improve its oncology diagnostic services.

FMI’s report includes profiles of some of the most prominent names in the market including F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., NeoGenomics Laboratories, Inc, HalioDx and Abcam plc. among others.

For Complete TOC @ https://www.futuremarketinsights.com/toc/rep-gb-5897

To Know More About PD-L1 Biomarkers Market

A new market research report published by Future Market Insights (FMI) on the global PD-L1 biomarkers market offers an executive-level blueprint of the market. It offers insights into demand trends and provides analysis of opportunities over the forecast period, 2020-2030. The report examines the market through four different segments – product, indication, end-use, and region. The report also provides extensive assessment of pricing by different key market dynamics, life cycle analysis, and technologies that are being deployed in the supply and product adoption across several end-use industries.

ESOMAR-certified consulting firm Future Market Insights’ report, projects a healthy growth, for optical coherence tomography (OCT) market. As per the report, the market is forecast to reach a valuation of US$ 1349.09 Mn over the forecast period of 2021 and 2031.

Growing application of OCT in ophthalmology across China, the U.K., Germany and Japan will bolster the demand of optical coherence tomography across the globe.

As per the FMI’s analysis, the optical coherence tomography market across Japan and China is anticipated to expand at over 9.8% and 4.6%, respectively in 2021. Growing prevalence of eye related disorders such as diabetic retinopathy, glaucoma and others will improve the adoption of OCT imaging systems.

Development of advanced OCT imaging systems coupled with increasing government & private organizations initiatives for eye care programs across the globe are propelling the adoption of OCT imaging systems.

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3362

Growing awareness and increasing innovation for the advanced OCT devices for the treatment of skin cancer and eye diseases have urged the manufacturers to incorporate real-time data for better outcomes, expanding their existing product ranges.

Based on the aforementioned factors, the OCT market is slated to expand at a robust pace of over 6.7% CAGR during the assessment period of 2021 and 2031.

Key Takeaways from FMI’s Optical Coherence Tomography Market Study

• Hospitals are anticipated emerge as primary end users of optical coherence tomography market, accounting for leading market share
• Preference for spectral domain-OCT will be higher as compared to swept source-OCT over the forecast period
• Increasing application of OCT in ophthalmology is expected to drive sales through 2031
• Germany and the U.K. will lead the Europe’s optical coherence tomography market on the back of rising cases of eye disorders across the region
• Japan is anticipated to emerge as a lucrative market backed by the rising development of advanced OCT imaging systems within healthcare sector
• China is anticipated to lead the East Asia market during the forecast period, accounting for over 4.6% market sales
• The U.S. is estimated to be the largest market for optical coherence tomography market attributed to be growing prevalence of eye related disorders

“Key players are increasing research and development activities for the development of advanced OCT imaging system for the early detection & treatment of eye-related disorders. This, in turn, is likely to omprovegrowth opportunities for the market players over the coming years,” says the FMI analyst. 

Optical Coherence Tomography Market Competitive Landscape

Future Market Insights, in its updated report, have profiled prominent players operating in optical coherence tomography market which include Leica Microsystems, Optovue Inc., Carl Zeiss Meditec AG, Santec Corporation, Heidelberg Engineering GmbH, Optopol Technology SP Z.O.O., Topcon Corporation, Michelson Diagnostic Ltd., Tomophase Inc., Moptim Imaging Technique, NIDEK Co. Ltd., and Sonostar Technologies Co. Ltd among others.

Optical coherence tomography systems manufacturers are actively focusing on expanding their product portfolios to improve their revenue generation.

Incorporation of advanced technology combined with the upgradation of its existing range of products is also one of the core strategies of market players to maintain their position in the industry.

The global optical coherence tomography market is dominated by top tier-1 market players that include Leica Microsystem (Sub. Danaher), Optovue Inc., and Zeiss Group (Carl Zeiss Meditec AG).

Targeted mergers and collaborations with top distribution channel partners is anticipated to be the key strategy to maintain their top position in the industry. Around 20% to 25% of global market revenue is contributed by the tier-1 players over the forecast period.

New product launches with the expansion of their existing product range is one of the common market strategy for the key players. For instance:

In March 2021, Premier Medical Imaging AI Inc., a medical technology company focusing to transform cancer surgery with ultra-high resolution, announced the 510 (k) clearance for its Perimeter’s Optical Coherence Tomography imaging system (v2.1) from the U.S. Food & Drug Administration (FDA), designed to examine tissue microstructures during surgical procedures.

In January 2021, Notal Vision announced the launch of its first ‘US Home-Based’ optical coherence tomography platform which was patient self-operated.

To gain more insights into the market with a detailed table of content and figures, click here:  https://www.futuremarketinsights.com/toc/rep-gb-3362

More Insights on the Global Optical Coherence Tomography Market

Future Market Insights, in its latest report, offers an incisive coverage on the global optical coherence tomography market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is classified on the basis of product type (spectral domain-OCT, swept source-OCT, and others), application type (ophthalmology, dermatology, cardiovascular, dental, and others), and end user (hospitals, ophthalmology clinics, dermatology clinics, dental clinics, ambulatory surgical centers, and others) across seven major regions (North America, Latin America, Eastern Europe, Asia Pacific excluding Japan, Western Europe, Japan and Middle East & Africa)

Femtech is a term used for female technology which involves the use of digital health tools including software, diagnostics, products, and services that are targeted at women’s health. According to a recent Future Market Insights (FMI) report, the global femtech market is estimated to hit a valuation of US$ 948.1 Mn in 2021, with a market CAGR of 15.0% during the forecast period (2021-2031).

Market demand is set to rise at a steady pace throughout the forecast period, majorly favoured by investments outside the boundaries of healthcare towards a branched approach involving domains such as workplace regulations, financial equity, and state legislation.

The primary factor supporting the femtech market to positive expansion in terms of growth and stability is the advent of digitalization and artificial intelligence. Technological advancements such as cloud-based informatics allow personalized solutions, driven by consumer input. This has given rise to affordable and accessible analysis in terms of personal health monitoring and diagnosis.

Click the link to get a free Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11761

Key market players have pushed for innovation and accessibility into customized digital solutions. This also includes the introduction of hands-free wearables which are assistive with the regular, day-to-day life of women across the globe.

Additionally, leading product developers in the femtech market work through commercial partners such as department stores, big-box retailers, hospitals, clinics, insurance companies, pharmacies and drugstores, private medical practices and e-commerce platforms to expand product sales prospects.

Key Takeaways from Femtech Market Study

• Menstrual health applications will drive market growth holding around a third of the market, supported by growing purchases from the working women demographic.
• Diagnostic services are projected to cover about 45% of the global market by 2031. This is aided by the growing accessibility of digital health services
• The U.S. holds a dominant share, valuing at over US$ 357.1 Mn by the end of 2021, supported by the presence of leading players and higher consumer acceptance.
• The U.K. and Germany dominate the Europe market, cumulatively accounting for more than 25% of the regional revenue.
• China is a leading market in East Asia, and is forecast to account for more than 50% of the regional value share owing to a vast consumer base.

“The advent of technological improvements in healthcare in the form of devices, applications, services, and products has increased the rate of diagnosis of reproductive disorders in terms of time management and treatments for women. This will aid growth through the upcoming decade,” says the FMI Analyst

Who is Winning?

Some of the leading companies operating in the femtech market are focusing on collaborations with leading institutions for increasing awareness among the population about the adoption of digital health services.

Collaborations with key pharmaceutical companies to launch customized products and services for the growing consumer base has led key players to retain their position in the market while expanding their product portfolio.

• Research collaboration in monitoring fetal heart rates through wearable ECG chips by between Bloomlife and Imec in 2019 has expectantly given rise to superior monitoring capabilities in maternity care.
• Femtech companies have integrated applications for tracking fertility and offer services such as in-vitro fertilization. Additionally, they also offer medical treatments and products such as wearables and hands-free devices.

Key market players covered by FMI include Clue, Aparito Limited, Bloomlife, Bonzun Health Information AB, Elvie, Ava Science Inc., Grace Health, iBreve, LactApp, Natural Cycles Nordic AB, Hera Med Ltd., Niramai Health, NURX Inc., SteadySense GmbH, Pregnolia AG, Willow, WOOM and B-wom.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-11761

Want More Insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global femtech market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the femtech market based on service (diagnostics, monitoring, therapeutic), application (general health and wellness, maternity care, menstrual health, pelvic and uterine healthcare, cancer and chronic disease), and end-user (direct-to-consumer, hospitals, surgical centres, fertility clinics, diagnostics centres) across seven major regions.

The prevalence of urological diseases – such as urinary retention, benign prostate hyperplasia (BPH), bladder obstruction, urinary incontinence, and prostate cancer – has witnessed a significant uptick in the recent past. According to the statistics of the Centers for Disease Control and Prevention (CDC), nearly 15-25% of hospitalized patients receive a urinary catheter annually. As the number of hospital admissions continues to rise year-on-year, there is a persistent need for foley catheters in hospitals, which are projected to remain a crucial end-use segment.

Likewise, the growing burden of urinary retention, a chronic condition in which individuals cannot voluntarily urinate, is propelling demand for foley catheters to facilitate easy drainage of urine. As per the estimates of the American Academy of Family Physicians (AAFP), approximately 4.5 to 6.8 per 1,000 men in the US suffer from urinary retention. As the incidence of disorders continues to grow across the world, the demand for foley catheters is poised to remain high for the years to come.

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7769

Along similar lines, the high prevalence of urinary incontinence, a condition that causes the urine to leak involuntarily, is projected to bestow remunerative opportunities to players in the foley catheters market. The severity of urinary incontinence rises with age, with men above 70 being the most affected. The expanding base of the geriatric population will continue to necessitate the usage of foley catheters.

Having analyzed and scrutinized all the aforementioned facets in its new market study, Future Market Insights (FMI) projects that the global foley catheters market will grow in value at a CAGR of nearly 5% between 2020 and 2030. Some of the key takeaways from the report include:

• The global foley catheters market is expected to surge past valuation of US$ 2.2 Bn by the end of 2030.
• By product type, 2-way foley catheters are poised to remain the most sought-out variants, owing to their wide availability and simple installation, and will hold more than half of the overall market value.
• Among materials, latex-based foley catheters are expected to gain an edge over their counterpart, silicon-based foley catheters, backed by their ability to reduce urethral irritation.
• Based on indication, urinary incontinence is expected to remain the largest segment, on the back of high incidence among geriatric population.
• North America will remain at the forefront of the regional landscape ascribed to high expenditure on medical aids coupled with new product approvals.
• Asia Pacific and Europe will continue to bestow remunerative opportunities to market players.

“With catheter-acquired infections being a major challenge to the adoption of foley catheters, manufacturers are focusing on developing products with materials and coatings that aid in reducing accumulation of bacteria, thus restraining the possibility of catheter-acquired infections among patients” remarks FMI analyst.

COVID-19 Impact on Foley Catheters Market

COVID-19 is expected to create slight fluctuations in the growth trajectory of the foley catheters market. There has been a notable shift in priorities of healthcare institutions, with treatment for COVID-19 patients being the utmost priority across the world. Hospitals in severely affected nations such as the US and India have deprioritized non-essential hospitalizations, leading to a downfall in the demand for foley catheters. With urology not being the most concerning healthcare issue currently, the sales of numerous urology care devices, including foley catheters are likely to witness a decline across hospitals. However, the demand for foley catheters in long-term care facilities is poised to remain unhinged through the pandemic, and will continue to drive the sales of these devices.

For Complete TOC @ https://www.futuremarketinsights.com/toc/rep-gb-7769

Who is Winning?

Major players in the market are focusing on developing advanced catheters that reduce the likelihood of the patient developing catheter-associated infections. To achieve the same, they are using novel materials and coatings, and are seeking approvals to commercialize their devices. On these lines,

• C.R Bard is using silver-ion and antimicrobial coatings in the production of foley catheters to eliminate the risk of catheter-associated infections when used for long periods.
• B. Braun Melsungen AG continues to develop its catheter product line named Actreen® catheters, designed specifically for urinary retention, and are coated with lubricants to make it comfortable and hygienic to use.
• In 2019, Safe Medical Design Inc., procured FDA approval to commercialize its new catheter designed to reduce to urethral trauma.

FMI’s report includes profiles of some of the most prominent names in the market including Teleflex Incorporated, Cardinal Health, C.R Bard, B. Braun Melsungen AG, Coloplast A/S, Medtronic plc, Flume, ConvaTec Group, VOTG Medical, Sterimed Group, Ribbel International Limited, Angiplast Private Limited, Mais India Medical Devices Private Limited, and JK Medirise.